These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 31188761)

  • 21. A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS.
    Bader S; Bhatti R; Mussa B; Abusanana S
    Womens Health (Lond); 2024; 20():17455057241234530. PubMed ID: 38444070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
    Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D
    Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration.
    Konstantinidou SK; Argyrakopoulou G; Simati S; Stefanakis K; Kokkinos A; Analitis A; Mantzoros CS
    Diabetes Obes Metab; 2024 Aug; 26(8):3147-3154. PubMed ID: 38757729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL; Bello NT
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.
    Niafar M; Pourafkari L; Porhomayon J; Nader N
    Arch Gynecol Obstet; 2016 Mar; 293(3):509-15. PubMed ID: 26660657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.
    Song JE; Ko HJ; Kim AS
    Drug Des Devel Ther; 2024; 18():845-858. PubMed ID: 38524878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
    Frøssing S; Nylander M; Chabanova E; Frystyk J; Holst JJ; Kistorp C; Skouby SO; Faber J
    Diabetes Obes Metab; 2018 Jan; 20(1):215-218. PubMed ID: 28681988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
    Jensterle M; Kravos NA; Pfeifer M; Kocjan T; Janez A
    Hormones (Athens); 2015; 14(1):81-90. PubMed ID: 25885106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome.
    Papaetis GS; Filippou PK; Constantinidou KG; Stylianou CS
    Clin Drug Investig; 2020 Aug; 40(8):695-713. PubMed ID: 32583294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States.
    Levin A; Kaur N; Mainoo NK; Perez A
    Clin Ther; 2022 Mar; 44(3):e35-e44. PubMed ID: 35105470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weight Loss Pharmacotherapy: Current and Future Therapies.
    Jordan G; Young S; Alemán JO
    Gastrointest Endosc Clin N Am; 2024 Oct; 34(4):591-608. PubMed ID: 39277293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome.
    Koiou E; Tziomalos K; Katsikis I; Kandaraki EA; Kalaitzakis E; Delkos D; Vosnakis C; Panidis D
    Gynecol Endocrinol; 2012 Jan; 28(1):20-4. PubMed ID: 21756081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obesity Pharmacotherapy.
    Saunders KH; Umashanker D; Igel LI; Kumar RB; Aronne LJ
    Med Clin North Am; 2018 Jan; 102(1):135-148. PubMed ID: 29156182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients.
    Ruan X; Song J; Gu M; Wang L; Wang H; Mueck AO
    Arch Gynecol Obstet; 2018 Jun; 297(6):1557-1563. PubMed ID: 29602978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
    Cho LW; Kilpatrick ES; Keevil BG; Coady AM; Atkin SL
    Clin Endocrinol (Oxf); 2009 Feb; 70(2):233-7. PubMed ID: 18547343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential.
    Brown SA; Izzy M; Watt KD
    Hepatology; 2021 May; 73(5):2051-2062. PubMed ID: 33047343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Comparison of New Pharmacological Agents for the Treatment of Obesity.
    Nuffer W; Trujillo JM; Megyeri J
    Ann Pharmacother; 2016 May; 50(5):376-88. PubMed ID: 26887340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls.
    Kahal H; Kilpatrick E; Rigby A; Coady A; Atkin S
    Gynecol Endocrinol; 2019 Feb; 35(2):142-145. PubMed ID: 30599799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current and emerging pharmacotherapies for obesity in Australia.
    Hocking S; Dear A; Cowley MA
    Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.
    Tziomalos K; Katsikis I; Papadakis E; Kandaraki EA; Macut D; Panidis D
    Hum Reprod; 2013 Mar; 28(3):785-93. PubMed ID: 23315058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.